Augmentation Therapy With Serotonin 5‐ HT 1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies

• Published in: Neuropsychopharmacology reports Vol. 45; no. 2; p. e70023
• Main Authors: Yamada, Risa, Wada, Ayumu, Stickley, Andrew, Newman‐Tancredi, Adrian, Sumiyoshi, Tomiki
• Format: Journal Article
• Language: English
• Published: United States 01.06.2025
• Subjects: Antidepressive Agents - administration & dosage; Antidepressive Agents - pharmacology; Cognition - drug effects; Depressive Disorder, Major - drug therapy; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Serotonin 5-HT1 Receptor Agonists - administration & dosage; Serotonin 5-HT1 Receptor Agonists - pharmacology; 5‐HT1A receptor partial agonists; cognitive impairment; 5‐HT1A receptor biased agonists; depression; azapirone derivative
• ISSN: 2574-173X; 2574-173X
• DOI: 10.1002/npr2.70023

The use of serotonin 5-HT receptor partial agonists (5-HT -PAs) as an add-on therapy has been associated with the enhancement of attention/processing speed in patients with schizophrenia. Also, 5-HT receptors have been shown to play a role in the pathophysiology of mood disorders. There is compelling evidence supporting that stimulation of 5-HT receptors accelerates antidepressant effects. Accordingly, this systematic review examines the ability of adjunctive treatment with 5-HT -PAs to improve cognitive function in patients with depressive symptoms. A literature search using PubMed, the Cochrane Library, and Web of Science databases was performed from 1987 to January 2024 to identify randomized controlled trials (RCTs) corresponding to the following inclusion criteria: (1) RCTs, (2) human studies; studies that (3) targeted patients with a psychiatric disorder (except for schizophrenia or schizoaffective disorder), (4) evaluated the effect of cognitive functions, (5) were written in English. From the 80 studies initially screened, three met the inclusion criteria. Two of these studies dealt with vascular depression while one focused on major depressive disorder (MDD). In MDD, combined treatment with buspirone and melatonin was more efficacious in ameliorating subjective cognitive disturbances compared to the use of buspirone alone or the use of a placebo. Likewise, the combination of escitalopram-tandospirone was more advantageous than escitalopram alone for improving executive function and verbal fluency in patients with vascular depression. Further studies with novel 5-HT receptor agonists are warranted to examine their potentially more robust benefits on cognitive performance in subjects suffering from mood deficits.